Company profile
Neumora Therapeutics, Inc. Common Stock
NASDAQ: NMRA · Healthcare · Biotechnology
PublicHQ Watertown, DECIK 0001885522Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 28DQ —GM —SS 47
v0.1 · 35/100 weight · pillars only
↑ market scale, workforce scale · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$236.9M
Employees
92
as of 2026-08-13
Market cap
$316.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$236.9M-$236.9M2025
Operating income-$241.2M-$241.2M2025
Total assets$191.0M$191.0M2025
Liabilities$87.2M$87.2M2025
Equity$103.9M$103.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Neumora Therapeutics, Inc. Common Stock’s financial profile?
Neumora Therapeutics, Inc. Common Stock earned -$236.9M in FY2025 net income.
Peers · Healthcare
PureTech Health plc——Mobia Medical, Inc. Common Stock——Scribe Therapeutics Inc.——Anavex Life Sciences Corp.——Turn Therapeutics Inc.——Alamar Biosciences, Inc.——Key facts
CEOPaul L. Berns
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, DE
ExchangeNASDAQ: NMRA
Employees92
IPO date2023-09-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.